01666nas a2200265   4500000000100000008004100001653002600042653001400068653002600082653002600108653002000134653001100154653001200165653001300177653001700190100001200207700001400219700001600233245006000249856006200309300000900371490000700380520099900387022001401386       2003                            d10aAnti-Bacterial Agents10aBlindness10aCost-Benefit Analysis10aDisability Evaluation10aHealth Behavior10aHumans10aPoverty10aTrachoma10aWorld Health1 aFrick K1 aHanson CL1 aJacobson GA00aGlobal burden of trachoma and economics of the disease.  uhttp://www.ajtmh.org/content/69/5_suppl_1/1.full.pdf+html  a1-100 v693 a<p>Interest in the economics of trachoma is high because of the refinement of a strategy to control trachomatous blindness, an ongoing global effort to eliminate incident blindness from trachoma by 2020, and an azithromycin donation program that is a component of trachoma control programs in several countries. This report comments on the economic distribution of blindness from trachoma and adds insight to published data on the burden of trachoma and the comparative costs and effects of trachoma control. Results suggest that 1) trichiasis without visual impairment may result in an economic burden comparable to trachomatous low vision and blindness so that 2) the monetary burden of trachoma may be 50% higher than conservative, published figures; 3) within some regions more productive economies are associated with less national blindness from trachoma; and 4) the ability to achieve a positive net benefit of trachoma control depends importantly on the cost per dose of antibiotic.</p>  a0002-9637